MAPT and Alzheimer disease: Furthermore, several works underline that blocking A2AR using pharmacological or genetic tools improves memory deficits and even pathology as well as parenchymal inflammation in different experimental transgenic AD models chronically developing either amyloid burden and Tau pathology (Orr et al., 2015, 2018; Laurent et al., 2016; Faivre et al., 2018; Silva et al., 2018).